首页> 外文期刊>Bioengineered >A novel adjuvant-free H fusion system for the production of recombinant immunogens in Escherichia coli: its application to a 12 kDa antigen from Cryptosporidium parvum.
【24h】

A novel adjuvant-free H fusion system for the production of recombinant immunogens in Escherichia coli: its application to a 12 kDa antigen from Cryptosporidium parvum.

机译:一种新型无佐剂H融合系统,用于在大肠杆菌中生产重组免疫原:将其应用于细小隐孢子虫(Cryptosporidium parvum)的12 kDa抗原中。

获取原文
获取原文并翻译 | 示例
       

摘要

The production of recombinant antigens in Escherichia coli and specific polyclonal antibodies for diagnosis and therapy is still a challenge for world-wide researchers. Several different strategies have been explored to improve both antigen and antibody production, all of them depending on a successful expression and immunogenicity of the antigen. Gene fusion technology attempted to address these challenges: fusion partners have been applied to optimise recombinant antigen production in E. coli, and to increase protein immunogenicity. Taking a 12-kDa surface adhesion antigen from Cryptosporidium parvum (CP12) by example, the novel H fusion partner was presented in this work as an attractive option for the development of recombinant immunogens and its adjuvant-free immunisation. The H tag (of only 1 kDa) efficiently triggered a CP12-specific immune response, and it also improved the immunisation procedure without requiring co-administration of adjuvants. Moreover, polyclonal antibodies raised against the HCP12 fusion antigen detected native antigen structures displayed on the surface of C. parvum oocysts. The H tag proved to be an advanced strategy and promising technology for the diagnosis and therapy of C. parvum infections in animals and humans, allowing a rapid and simple recombinant production of the CP12 antigen.
机译:在大肠杆菌中产生重组抗原和用于诊断和治疗的特异性多克隆抗体仍然是全世界研究人员的挑战。已经探索了几种不同的策略来改善抗原和抗体的产生,所有这些都取决于抗原的成功表达和免疫原性。基因融合技术试图解决这些挑战:融合伴侣已被用于优化大肠杆菌中重组抗原的产生,并提高蛋白质的免疫原性。以小隐隐孢子虫(CP12)的12 kDa表面粘附抗原为例,在这项工作中提出了新型H融合伴侣,作为开发重组免疫原及其无佐剂免疫的诱人选择。 H标签(仅1 kDa)有效地触发了CP12特异性免疫反应,并且还改善了免疫程序,而无需同时使用佐剂。此外,针对HCP12融合抗原的多克隆抗体检测到了在小球藻卵囊表面显示的天然抗原结构。 H标签被证明是一种诊断和治疗动物和人体内小球藻感染的先进策略和有前途的技术,可以快速,简单地重组生产CP12抗原。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号